Of these fusions, 16 (including ALK, ARAF, BRAF, FGFR1, FGFR3, RET, and ROS1) and 21 (including ABL1, GNAS, JAK2, and NRG1) were classified as either related to lung cancer, or as oncogenes that have not been reported in lung cancer, respectively (Fig. 2). This evidence concerns the gene JAK2 and lung cancer.